Labcorp's venture capital arm, Labcorp Venture Fund, focuses on strategic investments in healthcare, life science, oncology, and fem technology sectors. Its strategy is to partner with startups and founders across the healthcare continuum to advance innovative, data-driven, accessible, and personalized care, encompassing areas like diagnostics, precision medicine, digital health, and clinical trial optimization.
47% of their portfolio is in Biotech & Life Sciences. Deal activity increased 200% year-over-year (6 deals in the last 12 months). Their most common stage is series-b (41% of deals). Average disclosed round size is $39.2M (across 16 rounds with reported amounts).
Portfolio
17
Fund Size
$300M
Top Stage
Series B
Last 12 Mo
6
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Prenosis | Series A | $20M | Jan 2026 |
 Precede Biosciences | Series B | $63.5M | Jan 2026 |
 Emm | Seed | $9M | Nov 2025 |
 Mercy BioAnalytics, Inc. | Series B | $59M | Sep 2025 |
 PreciseDx | Unknown | $11M | Jun 2025 |
 Outcomes4Me Inc. | Series B | $21M | May 2025 |
| PreciseDx | Series B | $20.7M | Aug 2024 |
 Acclinate | Series A | $7M | May 2024 |
 Evvy | Series A | $14M | Sep 2023 |
 Adela, Inc. | Series B | $48M | Sep 2023 |
| VVital Bio | Series B | $48M | Jul 2023 |
 Vital Biosciences | Series A | $18.6M | Jul 2023 |
 Epic Sciences, Inc. | Series F | $43M | Jun 2022 |
 PathAI | Series C | $165M | May 2021 |
 Boston Microfluidics | Series A | $17.5M | Aug 2019 |
| OORIG3N, Inc. | Unknown | — | Jun 2017 |
 PetDx | Series B | $62M | — |
Top Co-Investors
Last updated: 16 April 2026